Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
5 participants
INTERVENTIONAL
2007-09-30
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Glutamate Transporter GLT1, in the Treatment of Bipolar Disorder
NCT00512616
Levetiracetam in the Management of Bipolar Depression
NCT00566150
Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram
NCT00562861
A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).
NCT05227209
Bipolar Disorder Study for Men and Women
NCT00056277
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
ceftriaxone
2g per day which will be administered IV via midline, 7 days a week for 4 weeks.
P
Saline solution
Saline solution will be administered IV via midline, 7 days a week for 4 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ceftriaxone
2g per day which will be administered IV via midline, 7 days a week for 4 weeks.
Saline solution
Saline solution will be administered IV via midline, 7 days a week for 4 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presence of a current major depressive episode on the SCID
* Score of 17 or greater on the HDRS
* Failure to respond to two previous medication trials
* Capable of giving voluntary written consent
Exclusion Criteria
* Significant current substance dependence/abuse within 3 months preceding the trial
* Significant history of intravenous drug abuse
* Active suicidal ideation
* Pregnant/lactating mothers
* Significant medical history
* Patients on anticoagulation treatment
* Patients who test positive for HIV or Hep B or C
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stanley Medical Research Institute
OTHER
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zubin Bhagwagar, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Yale University
Gerard Sanacora, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Yale University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yale University School of Medicine
New Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mineur YS, Picciotto MR, Sanacora G. Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. Biol Psychiatry. 2007 Jan 15;61(2):250-2. doi: 10.1016/j.biopsych.2006.04.037. Epub 2006 Jul 24.
Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Dykes Hoberg M, Vidensky S, Chung DS, Toan SV, Bruijn LI, Su ZZ, Gupta P, Fisher PB. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005 Jan 6;433(7021):73-7. doi: 10.1038/nature03180.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0704002567
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.